Real World Study Of Abiraterone Acetate And Docetaxel In Patients With Metastatic Hormone Sensitive Prostate Cancer

Objective : The aim is to explore the current state of real-world application of abiraterone acetate and docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer in a real-world setting.Methods:From January 2011 to December 2021,199 patients with metastatic radical hormone-sensitive prostate cancer were retrospectively collected in the Department of Urology of the First Affiliated Hospital of Xinjiang Medical University according to the diagnostic criteria,The initial treatment regimen was divided into Combined androgen blockade(CAB),Abiraterone acetate(AA)and Docetaxel(DOC)groups.Results : The population distribution characteristics of single-centre metastatic hormone-sensitive prostate cancer showed that75.38% were >65 years old,34.17% were previously diabetic,45.23% were previously hypertensive,and 62.81%,27.64% and 9.55% were in the CAB,abiraterone and chemotherapy groups respectively for the initial treatment regimen;there was no statistical difference in PSA remission and PSA level after six months of treatment between the three groups.levels in all three groups were not statistically different(P> 0.05),the three-year survival rates in the three groups were not statistically different(P> 0.05),and the mean survival times in the CAB,abiraterone acetate,and docetaxel chemotherapy groups were30.83,34.50,and 29.27 months;there were statistical differences in the three groups in terms of gastrointestinal symptoms,cardiotoxic reactions and haematological symptoms(P<0.05),and no statistical differences in terms of skin reactions,hepatotoxicity,nephrotoxicity and neurological symptoms(P>0.05),with a high proportion of grade 0-2adverse reactions and zero incidence of grade 3 or above adverse reactions;the treatment compliance of the three groups differed significantly.41.60%,69.09% and 89.47% in the CAB group,abiraterone group and chemotherapy group respectively,and 68.42% in the completion of docetaxel chemotherapy cycle with high intensity.Conclusion :(1)Single-centre metastatic hormone-sensitive prostate cancer in Xinjiang is characterised by advanced age,complex underlying disease,and significant differences in the choice of initial treatment regimen.(2)The effectiveness of the different initial treatment regimens is similar and needs to be further validated by long-term follow-up.(3)The safety and compliance of the different initial treatment regimens differed significantly,and the adverse effects were all within the acceptable range of patients,with no serious adverse effects of grade 3 or above.